Jpmorgan Chase & CO Abcam PLC Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$21.54 - $24.41 $122 Million - $138 Million	5,655,372 Added 1387.12%	6,063,077 $137 Million
Q2 2023 Aug 11, 2023	BUY	$12.62 - $24.47 $3.4 Million - $6.59 Million	269,293 Added 194.56%	407,705 $9.98 Million
Q1 2023 May 11, 2023	BUY	$12.98 - $17.1 $219,037 - $288,562	16,875 Added 13.88%	138,412 $1.86 Million
Q4 2022 Feb 13, 2023	BUY	$13.92 - $17.0 $606,884 - $741,166	43,598 Added 55.94%	121,537 $1.89 Million
Q3 2022 Nov 14, 2022	BUY	$13.36 - $16.75 $41,148 - $51,590	3,080 Added 4.11%	77,939 $1.17 Million
Q2 2022 Aug 11, 2022	BUY	$12.69 - $19.25 $911,332 - $1.38 Million	71,815 Added 2359.23%	74,859 $1.08 Million
Q1 2022 May 11, 2022	BUY	$15.5 - $23.89 $15,453 - $23,818	997 Added 48.71%	3,044 $56,000
Q4 2021 Feb 10, 2022	BUY	$20.04 - $23.84 $41,021 - $48,800	2,047 New	2,047 $48,000

1.03M

Ticker ABCM
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 229,044,992
Description
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.